Two technologies that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome have been recommended for use in draft guidance from NICE. It is the first time a NICE ...

Discontinued. Please note that following on from information provided to NICE by the company in January 2022, the appraisal was suspended from NICE’s work programme. As no further information has been ...

Are you a pharmaceutical company considering the International Recognition Procedure (IRP) for your UK market entry? While the IRP offers opportunities for faster access to the UK market, it also ...

Suggested remit: To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that ...

According to the study, technologies that received scientific advice took a median of 312 days to progress from marketing authorisation to NICE guidance publication. In contrast, those without such ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

AI encompasses the use of digital technology to create systems capable of performing tasks commonly thought to require human intelligence. This includes machine learning approaches. Given the rapid ...

The evaluation committee considered evidence submitted by Ipsen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...